Due to the specific interactions between the RS17 peptide and CD47 on tumor cells, as well as the innate tumor-homing abilities of the M1 EVs, the manufactured hybrid nanovesicles (LEV-RS17) displayed robust tumor-targeting ability and increased drug accumulation at tumor sites. The gene discussed is CD47; the disease is neoplasm.